---
document_datetime: 2025-01-27 15:52:10
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pregabalin-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pregabalin-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3602857
conversion_datetime: 2025-12-25 05:24:56.909416
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pregabalin Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 27/01/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000238644                        | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (IB) - To provide a revised RMP version to remove the important identified risk 'Abuse and drug dependence' in line with the reference product.                                                              |            |     |                 |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type IA / EMA/VR/0000245344    | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                                                      | 21/01/2025 |     |                 |
| Variation type IA_IN / EMA/VR/0000234970 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted | 31/10/2024 |     | Annex II and PL |
| Variation type IA_IN / EMA/VR/0000229762 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                | 08/10/2024 | N/A |                 |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.b Primary packaging site - Refused B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Refused                                                                                                                   |            |     |             |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IB / EMA/VR/0000221271 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted To update the SmPC sections 4.4 and 4.8 and section 3 in the PIL with 'suicidal ideation' as part of the observed withdrawal symptoms. | 28/08/2024 |     | SmPC and PL |
| Variation type IB / EMA/VR/0000174437 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template                                                                                                                                                                                                                                                                       | 20/05/2024 | N/A |             |

<div style=\"page-break-after: always\"></div>

|                                       | change) - Accepted To provide an updated RMP to align with the EPAR RMP summary available for the reference product Lyrica; in particular, to remove 'Pregnancy and Lactating women' from the missing information in the Summary of safety concerns. In addition, the marketing authorization holder has taken the opportunity to implement minor editorial changes in Annex IV.   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000165859 | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                   | 24/01/2024 | N/A |